

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently amended) A method for inhibiting thrombosis in an animal comprising administering an effective dose of an anti-coagulation factor IX/IXa monoclonal antibody having self-limiting neutralizing activity.

2. (self-limiting neutralizing activity) The method of claim 1 further comprising administering acetylsalicylic acid in combination with the anti-coagulation factor IX/IXa monoclonal antibody.

Claims 3-5 (Cancelled).

6. (Currently amended) The method of claims 1 or 2 wherein the ~~anti-Factor IX~~ anti-coagulation factor IX/IXa monoclonal antibody has the identifying characteristics of SB 249413, SB 249415, SB 249416, SB 2249417, SB 257731 or SB 257732.

7. (Currently Amended) The method of claims 1 or 2 wherein the ~~anti-Factor IX~~ anti-coagulation factor IX/IXa monoclonal antibody has the identifying characteristics of SB 249417.

Claims 8-9 (Cancelled).

10. (Original) The method of claim 1 or 2 wherein the thrombosis is associated with myocardial infarction, unstable angina, atrial fibrillation, stroke, renal damage, pulmonary embolism, deep vein thrombosis, percutaneous transluminal coronary angioplasty, disseminated intravascular coagulation, sepsis, artificial organs, shunts or prostheses.

Claims 11-38 (Cancelled).

39. (Previously presented) The method of claim 10 wherein the thrombosis is associated with stroke.

40. (Previously presented) The method of claim 10 wherein the thrombosis is associated with sepsis.

41. (Previously presented) The method of claim 1 wherein the anti-coagulation Factor IX/IXa antibody binds with an epitope of the Factor IX gla domain.

42. (Currently amended) The method of claim 41 wherein the epitope is located within residues 3-11 of the Factor IX gla domain.

43. (Previously presented) The method of claim 42 wherein the antibody has a binding affinity of at least 4 nM.